Gazyva Plus CHOP Brings No New Benefits to Diffuse Large B-Cell Lymphoma Patients in Phase 3 Study
News
Patients with previously untreated diffuse large B-cell lymphoma (DLBCL) given Gazyva/Gazyvaro (obinutuzumab) plus standard chemotherapy (CHOP) do not have higher progression-free survival rates than those treated with Rituxan/MabThera (rituximab), according to new data ... Read more